Cargando…
Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity
Colitis involves immune cell–mediated tissue injuries, but the contribution of epithelial cells remains largely unclear. Vanin-1 is an epithelial ectoenzyme with a pantetheinase activity that provides cysteamine/cystamine to tissue. Using the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-colitis model...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118186/ https://www.ncbi.nlm.nih.gov/pubmed/17145956 http://dx.doi.org/10.1084/jem.20061640 |
_version_ | 1782140968163606528 |
---|---|
author | Berruyer, Carole Pouyet, Laurent Millet, Virginie Martin, Florent M. LeGoffic, Aude Canonici, Alexandra Garcia, Stéphane Bagnis, Claude Naquet, Philippe Galland, Franck |
author_facet | Berruyer, Carole Pouyet, Laurent Millet, Virginie Martin, Florent M. LeGoffic, Aude Canonici, Alexandra Garcia, Stéphane Bagnis, Claude Naquet, Philippe Galland, Franck |
author_sort | Berruyer, Carole |
collection | PubMed |
description | Colitis involves immune cell–mediated tissue injuries, but the contribution of epithelial cells remains largely unclear. Vanin-1 is an epithelial ectoenzyme with a pantetheinase activity that provides cysteamine/cystamine to tissue. Using the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-colitis model we show here that Vanin-1 deficiency protects from colitis. This protection is reversible by administration of cystamine or bisphenol A diglycidyl ether, a peroxisome proliferator-activated receptor (PPAR)γ antagonist. We further demonstrate that Vanin-1, by antagonizing PPARγ, licenses the production of inflammatory mediators by intestinal epithelial cells. We propose that Vanin-1 is an epithelial sensor of stress that exerts a dominant control over innate immune responses in tissue. Thus, the Vanin-1/pantetheinase activity might be a new target for therapeutic intervention in inflammatory bowel disease. |
format | Text |
id | pubmed-2118186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21181862007-12-13 Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity Berruyer, Carole Pouyet, Laurent Millet, Virginie Martin, Florent M. LeGoffic, Aude Canonici, Alexandra Garcia, Stéphane Bagnis, Claude Naquet, Philippe Galland, Franck J Exp Med Articles Colitis involves immune cell–mediated tissue injuries, but the contribution of epithelial cells remains largely unclear. Vanin-1 is an epithelial ectoenzyme with a pantetheinase activity that provides cysteamine/cystamine to tissue. Using the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-colitis model we show here that Vanin-1 deficiency protects from colitis. This protection is reversible by administration of cystamine or bisphenol A diglycidyl ether, a peroxisome proliferator-activated receptor (PPAR)γ antagonist. We further demonstrate that Vanin-1, by antagonizing PPARγ, licenses the production of inflammatory mediators by intestinal epithelial cells. We propose that Vanin-1 is an epithelial sensor of stress that exerts a dominant control over innate immune responses in tissue. Thus, the Vanin-1/pantetheinase activity might be a new target for therapeutic intervention in inflammatory bowel disease. The Rockefeller University Press 2006-12-25 /pmc/articles/PMC2118186/ /pubmed/17145956 http://dx.doi.org/10.1084/jem.20061640 Text en Copyright © 2006, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Articles Berruyer, Carole Pouyet, Laurent Millet, Virginie Martin, Florent M. LeGoffic, Aude Canonici, Alexandra Garcia, Stéphane Bagnis, Claude Naquet, Philippe Galland, Franck Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity |
title | Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity |
title_full | Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity |
title_fullStr | Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity |
title_full_unstemmed | Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity |
title_short | Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity |
title_sort | vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118186/ https://www.ncbi.nlm.nih.gov/pubmed/17145956 http://dx.doi.org/10.1084/jem.20061640 |
work_keys_str_mv | AT berruyercarole vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT pouyetlaurent vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT milletvirginie vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT martinflorentm vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT legofficaude vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT canonicialexandra vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT garciastephane vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT bagnisclaude vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT naquetphilippe vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity AT gallandfranck vanin1licensesinflammatorymediatorproductionbygutepithelialcellsandcontrolscolitisbyantagonizingperoxisomeproliferatoractivatedreceptorgactivity |